Aurobindo Pharma’s subsidiary CuraTeQ Biologics has completed a Phase I trial investigating its BP11 biosimilar candidate to Genentech/Novartis’ Xolair (omalizumab), bringing the Indian company closer to global filings.
The Phase I trial, which compared subcutaneous BP11 to EU- and US-sourced Xolair in 165 healthy volunteers, met primary pharmacokinetic endpoints of maximum serum concentration and area
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?